EBR Systems reports Q2 commercial progress

• EBR Systems completed 46 WiSE commercial implants during the second quarter of 2026, bringing total implants in its pilot phase and limited market release to 117.
• The company expects to report quarterly revenue in the range of US$2.6 million, subject to quarter-end closing adjustments.
• Management is shifting its commercial focus towards deepening utilisation within already activated accounts rather than signing new hospital sites.

EBR Systems (ASX:EBR) reported 46 commercial implants for the second quarter of 2026 alongside preliminary revenue projections between US$2.6 million and US$3 million.

The company expanded its total cumulative purchasing contracts to 52 after securing 17 new agreements during the latest three-month period.

"The limited market release continues to advance, with 46 commercial implants completed during the quarter, bringing total commercial implants to 117," said EBR Systems President and CEO John McCutcheon.

The business also trained 26 new physicians during the quarter, lifting the total number of trained medical professionals to 90 across 30 active hospital sites.

Following the announcement, the EBR Systems share price was down at $0.27.

The company develops wireless cardiac pacing devices designed to treat heart failure by eliminating traditional pacemaker leads.